TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10221556

Group type: EXPERIMENTAL
Intervention: Borderline patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acute and chronic schizophrenics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic schizophrenics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discriminant analysis
Number of subjects: 0
Study: 7602002

Group type: COMPARATOR
Intervention: Standard education protocol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard education and 30 minutes of verbal instruction
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Standard education and a medication schedule
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Standard education, a medication schedule, and 30 minutes of verbal instruction
Number of subjects: 42
Study: 2225292

Group type: EXPERIMENTAL
Intervention: alfentanil 30 micrograms.kg‐1 (ALF 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: alfentanil 45 micrograms.kg‐1 (ALF 45)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: alfentanil 60 micrograms.kg‐1 (ALF 60)
Number of subjects: 60

Group type: COMPARATOR
Intervention: normal saline (PLAC)
Number of subjects: 60
Study: 27461

Group type: EXPERIMENTAL
Intervention: Vaccine administered by aerosol route, three times a week for 5 weeks (Group I)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 104
Study: 31756911

Group type: EXPERIMENTAL
Intervention: UltraRice Original (URO)
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: UltraRice New (URN)
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: NutriRice
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Unfortified rice (placebo)
Number of subjects: 1950
Study: 27943546

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg once-daily or twice-daily)
Number of subjects: 4996

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4996
Study: 25940724

Group type: EXPERIMENTAL
Intervention: O3-FAs 3.3 g daily for 24 weeks
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo (soybean/corn oil) daily for 24 weeks
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: O3-FAs
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: O3-FAs and Placebo
Number of subjects: 249
Study: 24015698

Group type: EXPERIMENTAL
Intervention: Combination of bioactive food ingredients (capsaicinoids, epigallocatechin gallate, piperin, and l-carnitine)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 21988035

Group type: EXPERIMENTAL
Intervention: collodion‐Ten20
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hypafix‐Ten20
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hypafix‐Elefix
Number of subjects: 100
Study: 19822394

Group type: EXPERIMENTAL
Intervention: Active rTMS of M1
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Active rTMS of DLPFC
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Active rTMS of M1 or DLPFC
Number of subjects: 52
Study: 17094387

Group type: EXPERIMENTAL
Intervention: Combination therapy (somatostatin analog octreotide 20 mg i.m. every 28 days + oral dexamethasone 4 mg daily for 1 month, reduced to 1 mg daily by the fourth month, with a 1 mg daily maintenance dose thereafter + zoledronate 4 mg i.v. every 4 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Zoledronate only
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 38
Study: 15106005

Group type: EXPERIMENTAL
Intervention: Submaximal muscle actions at 20% increments from 20% to 80% peak torque (PT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Submaximal muscle actions
Number of subjects: 12
Study: 11718252

Group type: EXPERIMENTAL
Intervention: Tonsillotomy using a CO2 laser
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard tonsillectomy
Number of subjects: 43
Study: 9703407

Group type: EXPERIMENTAL
Intervention: Tepoxalin 50 mg twice daily for 3.5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tepoxalin 200 mg twice daily for 3.5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tepoxalin (400 mg)
Number of subjects: 0
Study: 8023548

Group type: EXPERIMENTAL
Intervention: Interferon-alpha with vaccine (20 micrograms Engerix-B + 1 million units of interferon-alpha)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo with vaccine (20 micrograms Engerix-B + saline placebo)
Number of subjects: 176
Study: 2685180

Group type: EXPERIMENTAL
Intervention: Histopathologic peer review
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Grading highly malignant soft tissue sarcoma in two grades (III and IV)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy multicenter trial
Number of subjects: 240
Study: 803830

Group type: EXPERIMENTAL
Intervention: Pyridinol carbamate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30732996

Group type: EXPERIMENTAL
Intervention: Low-dose ferrous sulfate (1-3 mg/kg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus plantarum 299v (LP299v)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no probiotic)
Number of subjects: 0
Study: 29078256

Group type: EXPERIMENTAL
Intervention: High sensitivity C-reactive protein (hsCRP) levels at randomization (22-34 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adiponectin levels at randomization (22-34 weeks)
Number of subjects: 100
Study: 27580595

Group type: EXPERIMENTAL
Intervention: rHuEpo (24,000 IU, 3 intravenous doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: rHuEpo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Duration of operation
Number of subjects: 36
Study: 23793486

Group type: EXPERIMENTAL
Intervention: Web-based data collection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone data collection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-administered (mailed) questionnaires
Number of subjects: 0
Study: 21711467

Group type: EXPERIMENTAL
Intervention: 308-nm xenon chloride excimer laser (EL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Narrow-band ultraviolet B (NB-UVB)
Number of subjects: 14
Study: 20821281

Group type: EXPERIMENTAL
Intervention: 23 gauge needle
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 25 gauge needle
Number of subjects: 155
Study: 17673038

Group type: EXPERIMENTAL
Intervention: Weight loss (diet and exercise)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Weight loss and metformin (500 mg three times daily)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Weight loss and rosiglitazone (4 mg once daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Weight loss
Number of subjects: 106
Study: 15672210

Group type: EXPERIMENTAL
Intervention: Raloxifene treatment
Number of subjects: 0
Study: 12001016

Group type: EXPERIMENTAL
Intervention: Oral load of 300 ml of magnesium-rich mineral water (1.2 mmol Mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous injection of (28)Mg
Number of subjects: 10
Study: 10048795

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Equal mixture (M) treatment (33% protein)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-Fat (HF) treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) treatment
Number of subjects: 16
Study: 9395624

Group type: EXPERIMENTAL
Intervention: Self-hypnosis relaxation techniques taught the night prior to surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 1919343

Group type: EXPERIMENTAL
Intervention: Permucosal needle aspiration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Admission to hospital and treatment with intravenous antibiotics
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Culture of pus
Number of subjects: 60
Study: 6797782

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-estradiol contraceptive vaginal rings (2 sizes)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Nordette (oral contraceptive)
Number of subjects: 1500
Study: 6360689

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 31335267

Group type: EXPERIMENTAL
Intervention: Narrative message
Number of subjects: 467

Group type: COMPARATOR
Intervention: Nonnarrative message
Number of subjects: 467
Study: 29140444

Group type: EXPERIMENTAL
Intervention: 1-2 doses of bivalent virus-like particle (VLP) norovirus vaccine candidate formulations
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 1-2 doses of 15 μg GI.1/50 μg GII.4c formulation
Number of subjects: 420

Group type: COMPARATOR
Intervention: Intramuscular control vaccine (hepatitis A)
Number of subjects: 420
Study: 26562363

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (low dose: target plasma concentration of 0.2 ng/ml)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (high dose: target plasma concentration of 0.6 ng/ml)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control PET scan (no dexmedetomidine)
Number of subjects: 6
Study: 24768130

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 85
Study: 22260823

Group type: EXPERIMENTAL
Intervention: Rikkunshito
Number of subjects: 27

Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 27
Study: 19709893

Group type: EXPERIMENTAL
Intervention: Thoracic epidural blockade (TEB)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Paravertebral blockade (PVB)
Number of subjects: 44
Study: 17401007

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate with intravenous high-dose methotrexate (1 g/m2)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate with 18 Gy cranial radiation
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate with 24 Gy cranial radiation
Number of subjects: 456
Study: 16267721

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 0
Study: 12943879

Group type: EXPERIMENTAL
Intervention: History of peripheral vascular disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study: 10609695

Group type: EXPERIMENTAL
Intervention: Rating scale for post-stroke psychiatric symptoms
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Global Change Scale (GCS)
Number of subjects: 30
Study: 8946434

Group type: COMPARATOR
Intervention: d-fenfluramine HCl 0.5 mg/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: d-fenfluramine HCl 1.0 mg/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: d,l-fenfluramine HCl 1.0 mg/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: d,l-fenfluramine HCl 0.5 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: d-fenfluramine HCl
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: d,l-fenfluramine HCl
Number of subjects: 11
Study: 2014928

Group type: COMPARATOR
Intervention: Aqueous BSA solution (10 mg/mL) in a titrated double‐blind, placebo‐controlled bronchial inhalation challenge.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Albuterol metered dose inhaler and avoidance of laboratory exposure to BSA.
Number of subjects: 1
Study: 6750813

Group type: EXPERIMENTAL
Intervention: 100 g oral glucose load
Number of subjects: 85
Study: 30935317

Group type: EXPERIMENTAL
Intervention: Microembolic Signals (MES) detection
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Presence of MESs
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Recent ischemic events
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High mean flow velocities
Number of subjects: 48
Study: 27678151

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (12g daily for 12 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no BCAA supplementation)
Number of subjects: 18
Study: 26448183

Group type: EXPERIMENTAL
Intervention: Positive verbal suggestion (inert capsule said to be effective for reducing physical sensitivity)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Positive imagery (imagining best possible health)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control verbal suggestion (inert capsule said to be effective for reducing physical sensitivity in minority of users)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control imagery (imagining a typical day)
Number of subjects: 116
Study: 23839537

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (ADV)
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Intradermal vaccine (IDV)
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Subunit vaccine (TIV)
Number of subjects: 911

Group type: COMPARATOR
Intervention: All vaccines (IDV, ADV, TIV)
Number of subjects: 911
Study: 21223356

Group type: EXPERIMENTAL
Intervention: SB-742457 (50 mg) + Risperidone (2 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Risperidone (2 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: SB-742457 (50 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19164438

Group type: EXPERIMENTAL
Intervention: Acute vertebral artery dissection (VAD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 17551253

Group type: EXPERIMENTAL
Intervention: Epoietin beta
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15507864

Group type: EXPERIMENTAL
Intervention: Low-dose balsalazide (2.25 g/day) plus VSL#3 (3 g/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medium-dose balsalazide alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Balsalazide/VSL#3
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Balsalazide with or without VSL#3
Number of subjects: 90
Study: 12622761

Group type: EXPERIMENTAL
Intervention: Controlled-release (Entocort) capsules
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard budesonide capsules
Number of subjects: 14
Study: 10052810

Group type: EXPERIMENTAL
Intervention: Air reduction (AR group)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Barium enema reduction (BE group)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Saline reduction under ultrasound guidance (US group)
Number of subjects: 147
Study: 8588056

Group type: EXPERIMENTAL
Intervention: buspirone 15 or 20 mg tid
Number of subjects: 43

Group type: COMPARATOR
Intervention: lorazepam 3 or 4 mg tid
Number of subjects: 43

Group type: COMPARATOR
Intervention: lorazepam
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: buspirone
Number of subjects: 43
Study: 1778878

Group type: EXPERIMENTAL
Intervention: Once-daily amikacin dosing (od)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Twice-daily amikacin dosing (bd)
Number of subjects: 348
Study: 7040494

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no drug treatment)
Number of subjects: 14
Study: 29864052

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (Running only)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All groups (SS, DS, Control)
Number of subjects: 32
Study: 30664639

Group type: EXPERIMENTAL
Intervention: 10 mg fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29945396

Group type: EXPERIMENTAL
Intervention: modified Buzhong Yiqi decoction combined with pelvic floor muscle exercises-biofeedback-electrostimulation
Number of subjects: 186

Group type: COMPARATOR
Intervention: pelvic floor muscle exercises-biofeedback-electrostimulation
Number of subjects: 186
Study: 27417334

Group type: EXPERIMENTAL
Intervention: Pouring apple juice first
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pouring water first
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pouring milk before cereals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pouring cereals before milk
Number of subjects: 0
Study: 24073841

Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lurasidone 120 mg/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lurasidone (80-160 mg/day)
Number of subjects: 25
Study: 23311171

Group type: EXPERIMENTAL
Intervention: Jiawei Shengdan Louxie Sini Fang
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine (control)
Number of subjects: 0
Study: 20195085

Group type: EXPERIMENTAL
Intervention: Whole body compression garment (CG)
Number of subjects: 20
Study: 18188749

Group type: EXPERIMENTAL
Intervention: Proactive recruitment strategy (telephoning women whose phone numbers were purchased from a marketing firm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reactive recruitment strategies (advertisements, press releases, direct mail, Web placement, health care provider outreach)
Number of subjects: 0
Study: 15919639

Group type: EXPERIMENTAL
Intervention: Behavioral goal to reduce fat intake
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Behavioral goal to increase fruits and vegetables (F&V) consumed
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Behavioral goal to increase physical activity (PA)
Number of subjects: 422
Study: 12627352

Group type: EXPERIMENTAL
Intervention: Lamivudine therapy
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Lamivudine therapy for up to 4 years
Number of subjects: 794
Study: 10487307

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8865085

Group type: EXPERIMENTAL
Intervention: Visual stimulation with a moving target using rotating prismatic glasses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pursuing a luminous target on a stable visual background
Number of subjects: 0
Study: 1321194

Group type: EXPERIMENTAL
Intervention: Sodium intake at 120 mmol/day for 6 days, followed by 10 mmol/day for 8 days, then 400 mmol/day for 8 days (Greifswald study)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sodium intake at 10, 200 or 400 mmol/day for 7 days (Indianapolis study)
Number of subjects: 78
Study: 6435772

Group type: EXPERIMENTAL
Intervention: Alfentanil (new analgesic supplement)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional anaesthesia with halothane
Number of subjects: 0
Study: 29688915

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 29236238

Group type: EXPERIMENTAL
Intervention: 5-week online guided self-help intervention based on problem-solving therapy
Number of subjects: 89

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 89

Group type: COMPARATOR
Intervention: Non-CNS cancer controls
Number of subjects: 89
Study: 26896473

Group type: COMPARATOR
Intervention: Tetrahydrobiopterin (BH4) 400 mg single dose
Number of subjects: 33

Group type: COMPARATOR
Intervention: Tetrahydrobiopterin (BH4) 400 mg once daily for 1 week
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (acute regimen)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (short-term regimen)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Tetrahydrobiopterin (BH4)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 24876957

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg and Dexamethasone 8 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 21553153

Group type: EXPERIMENTAL
Intervention: Positive Deviance (PD) peer learning groups
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (students not working in PD peer learning groups)
Number of subjects: 50
Study: 20010616

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment for prophylaxis of relative adrenal insufficiency
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: High cortisol concentrations
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Low cortisol concentrations
Number of subjects: 350
Study: 17950452

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 98
Study: 16085580

Group type: EXPERIMENTAL
Intervention: Emory Cardiac Tool Box (ECTB)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 4D-MSPECT
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Quantitative Gated SPECT (QGS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: cMRI
Number of subjects: 70
Study: 12461263

Group type: EXPERIMENTAL
Intervention: MS-325
Number of subjects: 12
Study: 10601936

Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anesthetic cream (lidocaine and prilocaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dorsal penile nerve block with lidocaine
Number of subjects: 60
Study: 8942887

Group type: EXPERIMENTAL
Intervention: Internal fixation (IF)
Number of subjects: 21

Group type: COMPARATOR
Intervention: External fixation (EF)
Number of subjects: 21
Study: 8354766

Group type: EXPERIMENTAL
Intervention: Moclobemide (400 mg/day)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Clomipramine (150 mg/day)
Number of subjects: 115
Study: 3726718

Group type: EXPERIMENTAL
Intervention: Moxalactam (2 grams every 12 hours)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Gentamicin (80 mg every 8 hours) plus Clindamycin (600 mg every 6 hours)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Gentamicin plus Clindamycin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 42
Study: 29855839

Group type: EXPERIMENTAL
Intervention: Trans-model communications training course
Number of subjects: 64

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 64
Study: 27207626

Group type: EXPERIMENTAL
Intervention: Feedback on asthma measure
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: Feedback on antihypertensive medications
Number of subjects: 1814